NASDAQ: CGON · Life Sciences · 4 alerts · CIK 1991792
Share price
$84.78Close, Nov 16
Market cap
$7.57B
Shares outstanding
89.32MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CG Oncology, Inc. filings on SEC EDGAR ↗
CG Oncology announced positive topline results from its Phase 3 PIVOT-006 registrational trial of cretostimogene in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint, showing a 68% reduction in the risk of recurrence (hazard ratio of 0.32) compared to the control arm, with no Grade 3 or higher treatment-related adverse events reported.
CG Oncology reported a net loss of $196.1 million for the first nine months of 2026, driven by a significant increase in research and development expenses to $137.6 million. The company strengthened its balance sheet through a follow-on public offering that raised $391.6 million, ending the period with over $984 million in cash and marketable securities.
CG Oncology reported third quarter 2026 financial results, highlighting a cash position of $984.5 million which is expected to fund operations through 2029. The company is approaching several clinical milestones, including anticipated Phase 3 topline data for PIVOT-006 in November 2026 and the completion of its BLA submission for BCG-unresponsive NMIBC in Q4 2026.
Term
Q3 2026
“We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders.”
Arthur Kuan, Chairman, President & Chief Executive Officer
CG Oncology Director Leonard E. Post Sells $62.1K of Stock
Leonard E. Post, Director, sold 1,000 shares of CG Oncology, Inc. at $61.65 to $62.48 a share (average $62.06) in 2 transactions, worth $62.1K in total on Oct 15, 2026. Shares held after the trade: 0 (-100.0%).